Barclays PLC Mainz Biomed N.V. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding MYNZ
# of Institutions
12Shares Held
191KCall Options Held
0Put Options Held
0-
Vontobel Holding Ltd.45KShares$212,8500.0% of portfolio
-
Northern Trust Corp Chicago, IL29.9KShares$141,5870.0% of portfolio
-
Steward Partners Investment Advisory, LLC29KShares$137,1700.0% of portfolio
-
Two Sigma Securities, LLC New York, NY23.5KShares$111,2250.0% of portfolio
-
Geode Capital Management, LLC Boston, MA15.2KShares$71,8430.0% of portfolio
About MAINZ BIOMED N.V.
- Ticker MYNZ
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 14,483,000
- Market Cap $68.5M
- Description
- Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments...